Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence | OMICS International | Abstract
ISSN: 2155-6105

Journal of Addiction Research & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence

Kenneth Blum1,4,5,6,8-10*, Marlene Oscar-Berman2, Nicholas DiNubile3, John Giordano4, Eric R Braverman1,5, Courtney E Truesdell5, Debmalya Barh6 and Rajendra Badgaiyan7

1Department of Psychiatry, McKnight Brain Institute, University of Florida, College of Medicine, Gainesville, FL, USA

2Departments of Psychiatry and Anatomy & Neurobiology, Boston University School of Medicine, and Boston, VA Healthcare System, Boston, MA, USA

3Department of Orthopaedic Surgery at the University of Pennsylvania, Philidelphia, Pennslyvania, USA

4Department of Holistic Medicine, National Institute for Holistic Addiction STudies, Inc. North Miami Beach, Fl, USA

5Department of Clinical Neurology, PATH Foundation NY, New York, NY, USA

6Center for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purbe Medinpur, West Bengal, India

7Department of Psychiatry, University at Buffalo & Harvard University, Psychiatrist, WNY VAMC, Buffalo, NY, USA

8Dominion Diagnostics, LLC., North Kingstown, Rhode Island, USA

9Department of Addiction Research & Therapy, Malibu Beach Recovery Center, Malibu Beach California, USA

10Department of Nutrigenomics, IGENE LLC., Austin Texas, USA

*Corresponding Author:
Kenneth Blum
Department of Psychiatry
McKnight Brain Institute
University of Florida
College of Medicine, Gainesville, FL, USA
Email: [email protected]

Received date: September 02, 2013; Accepted date: October 23, 2013; Published date: October 31, 2013

Citation: Blum K, Oscar-Berman M, DiNubile N, Giordano J, Braverman ER, et al. (2013) Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence. J Addict Res Ther 4:163. doi:10.4172/2155-6105.1000163

Copyright: © 2013 Blum K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


The endemic of legal opioid iatrogenic induced prescription drug abuse is of major world-wide concern. Understanding pain pathways and the role of dopaminergic tone in the neurophysiology of pain relief provides potential therapeutic solutions. A 2011 NIDA report indicated that approximately 8.7% of the entire US population above the age of 12 years has used a psychoactive drug within the past 30 days. It has been reported that the overall genetic contribution to the variance of Substance Use Disorder (SUD) was approximately 60% but each candidate gene evaluated by GWAS was relatively small. In an attempt to combat this global endemic we are proposing a number of alternative strategies. Prevention of death due to opioid overdose and attenuation of prescription abuse should focus on strategies that target 1) high-dosage medical users; 2) persons who seek care from multiple doctors; 3) persons involved in “drug diversion”; 4) genetic testing for addiction liability and severity indices; 5) non-pharmacolgical analgesic treatments such as electrotherapy.